Modulation of YY1 and p53 expression by transforming growth factor-β3 in prostate cell lines

Cytokine

Volumn 56, Issue 2, 2011, Pages 403-410

  Caggia, Silvia ^a   Libra, Massimo ^a   Malaponte, Grazia ^a   Cardile, Venera ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Apoptosis; Cancer; NO; PI3K Akt; TGF 3

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR YY1; TRANSFORMING GROWTH FACTOR BETA3;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL ASSAY; CELL SPECIFICITY; CELL STIMULATION; CELL STRAIN DU 145; CELL STRAIN LNCAP; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INCUBATION TIME; INTRACELLULAR SIGNALING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA3; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053302623     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.06.024     Document Type: Article

References (63)

1. Seoane J. The TGFβ pathway as a therapeutic target in cancer. Clin Transl Oncol 2008, 10:14-19.
2. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998, 67:753-791.
3. Akhurst R.J., Derynck R. TGF-β signaling in cancer a double-edged sword. Trends Cell Biol 2001, 11:S44-51.
4. Wakefield L.M., Roberts A.B. TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002, 12:22-29.
5. Bakin A.V., Tomlinson A.K., Bhowmick N.A., Moses H.L., Arteaga C.L. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000, 275:36803-36810.
6. Bakin A.V., Rinehart C., Tomlinson A.K., Arteaga C.L. P38 mitogen-activated protein kinase is required for TGFβ mediated fibroblastic trans differentiation and cell migration. J Cell Sci 2002, 115:3193-3206.
7. Dumont N., Arteaga C.L. Targeting the TGFβ signaling network in human neoplasia. Cancer Cell 2003, 3:531-536.
8. Bierie B., Moses H.L. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:117-129.
9. Shi Y., Lee J.S., Galvin K.M. Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta 1997, 1332:F44-66.
10. He Y., Casaccia-Bonefil P. The Yin and Yang of YY1 in the nervous system. J Neurochem 2008, 106:1493-1502.
11. Donohoe M.E., Zhang X., McGinnis L.L., Biggers J., Li E., Shi Y. Targeted disruption mouse Yin Yang 1 transcription factor results in peri-implantation lethality. Mol Cell Biol 1999, 19:7237-7244.
12. Hyde-DeRuyscher R.P., Jennings E., Shenk T. DNA binding sites for activator/repressor YY1. Nucleic Acids Res 1995, 23:4457-4465.
13. Yakovleva T., Kolesnikova L., Vukojević V., Gileva I., Tan-No K., Austen M., et al. YY1 binding to a subset of p53 DNA-target sites regulates p53-dependent transcription. Biochem Biophys Res Commun 2004, 318:615-624.
14. Zaravinos A., Spandisos D.A. YinYang 1 expression in human tumors. Cell Cycle 2010, 9:512-522.
15. Thomas M.J., Seto E. Unlocking the mechanisms of transcription factor YY1: are the chromatin modifying enzymes the key?. Gene 1999, 236:197-208.
16. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
17. Gottlieb T.M., Oren M. P53 in growth control and neoplasia. Biochim Biophys Acta 1996, 1287:77-102.
18. Gire V., Wynford-Thomas D. Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol Cell Biol 1998, 18:1611-1621.
19. Poyak K., Xia Y., Zewier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature 1997, 6648:300-310.
20. Hall P.A., Lane D.P. Tumor suppressors: a developing role for p53?. Curr Biol 1997, 7:R144-147.
21. Cross S.M., Sanchez C.A., Morgan C.A., Schimke M.K., Ramel S., Idzerda R.L., et al. A p53-dependent mouse spindle checkpoint. Science 1995, 267:1353-1356.
22. Soddu S., Blandino G., Citro G., Scardigli R., Piaggio G., Ferber A., et al. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 1994, 83:2230-2237.
23. Sugrue M.M., Shin D.Y., Lee S.W., Aaronson S.A. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci USA 1997, 94:9648-9653.
24. Sui G., Affar E.B., Shi Y., Brignone Wall N.R., Yin P., Donohoe M., et al. Yin Yang 1 is a negative regulator of p53. Cell 2004, 117:859-872.
25. Bain M., Sinclair J. Targeted inhibition of the transcription factor YY1 in an embryonal carcinoma cell line results in retarded cell growth, elevated levels of p53 but no increase in apoptotic cell death. Eur J Cell Biol 2005, 84:543-553.
26. Affar el B., Gay F., Shi Y., Liu H., Huarte M., Wu S., et al. Essential dosage-dependent functions of the transcription factor Yin Yang 1 in late embryonic development and cell cycle progression. Mol Cell Biol 2006, 26:3565-3581.
27. He Y., Dupree J., Wang J., Sandoval J., Li J., Liu H., et al. The transcription factor Yin Yang 1 is essential for oligodendrocyte progenitor differentiation. Neuron 2007, 55:217-230.
28. Seligson D., Horvath S., Huerta-Yepez S., Hanna S., Garban H., Roberts A., et al. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol 2005, 27:131-141.
29. Zhang Y.E. Non Smad pathways in TGF-β signaling. Cell Res 2009, 19:128-139.
30. Stambolic V., MacPherson D., Sas D., Lin Y., Snow B., Jang Y., et al. Regulation of PTEN transcription by p53. Mol Cell 2001, 8:317-325.
31. Wymann M.P., Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1998, 1436:27-50.
32. Sandau K., Pfeilschifter J., Brune B. Nitric oxide and superoxide induced p53 and Bax accumulation during mesangial cell apoptosis. Kidney Int 1997, 52:378-386.
33. Brune B., Schneiderhan N. Nitric oxide evoked p53-accumulation and apoptosis. Toxicol Lett 2003, 139:119-123.
34. Feng P., Li T., Guan Z., Franklin E.B., Costello L. The involvement of Bax in zinc-induced mitochondrial apoptogenesis in malignant prostate cells. Mol. Cancer 2008, 7:25-30.
35. Turley R.S., Finger E.C., Hempel N., How T., Fields T.A., Blobe G.C., et al. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 2007, 67:1090-1098.
36. Mythreye K., Blobe G.C. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA 2009, 106:8221-8226.
37. Dahiya R., Lee C., Haughney P.C., Chui R., Ho R., Deng G. Differential gene expression of transforming growth factors alpha and beta, epidermal growth factor, keratinocyte growth factor, and their receptors in fetal and adult human prostatic tissues and cancer cell lines. Urology 1996, 48:963-970.
38. Elliott R.L., Blobe G.C. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005, 23:2078-2093.
39. Yang L. TGFβ and cancer metastasis: an inflammation link. Cancer Metastasis Rev 2010, 29:263-271.
40. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999, 96:4240-4245.
41. Gronroos E., Terentiev A.A., Punga T., Ericsson J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci USA 2004, 101:12165-12170.
42. Dey A., Lane D.P., Verma C. Modulating the p53 pathway. Sem Cancer Biol 2010, 20:724-730.
43. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
44. Dornan D., Wertz I., Shimizu H., Arnott D., Frantz G.D., Dowd P., et al. The ubiquitin ligase cop1 is a critical negative regulator of p53. Nature 2004, 429:86-92.
45. Leng R.P., Lin Y., Ma W., Wu H., Lemmers B., Chung S., et al. L Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003, 112:779-791.
46. Hock A., Vousden K.H. Regulation of the p53 pathway by ubiquitin and related proteins. Int J Biochem Cell Biol 2010, 42:1618-1621.
47. Vivanco I., Sawyers C.L. The phosphatidylinositide 3-kinase/AKT in radiation responses. Nat Rev Cancer 2002, 2:489-501.
48. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., et al. Activation of NF-kappaB and upregulation of intracellular antiapoptotic proteins via IGF-1/AKT signalling in human multiple myeloma cells: therapeutic implications. Oncogene 2002, 21:5673-5683.
49. Jansen B., Schlagbauer-Wadl H., Brown B.D., van Elsas A., Müller M., Wolff K., Eichler H.G., Pehamberger H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998, 4:232-234.
50. Gleave M., Tolcher A., Miyake H., Nelson C., Brown B., Beraldi E., et al. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999, 5:2891-2898.
51. Miyake H., Tolcher A., Gleave M. Chemosensitization and delayed androgen independent recurrence prostate cancer with the use of antisense bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000, 92:34-41.
52. Biroccio A., Candiloro A., Mottolese M., Sapora O., Albini A., Zupi G., et al. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma cell line. FASEB J 2000, 14:652-660.
53. Nakaya N., Lowe S.W., Taya Y., Chenchik A., Enikolopov G. Specific pattern of p53 phosphorylation during nitric oxide-induced cell cycle arrest. Oncogene 2000, 19:6369-6375.
54. Wang X., Michael D., de Murcia G., Oren M. P53 activation by nitric oxide involves down-regulation of Mdm2. J Biol Chem 2002, 277:15697-15702.
55. Lala P.K., Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001, 2:149-156.
56. Messmer U.K., Ankarcrona M., Nicotera P., Brune B. P53 expression in nitric oxide-induced apoptosis. FEBS Lett 1994, 355:23-26.
57. Ambs S., Hussain S.P., Harris C.C. Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J. 1997, 11:443-448.
58. Forrester K., Ambs S., Lupold S.E., Kapust R.B., Spillare E.A., Weinberg W.C., et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996, 93:2442-2447.
59. Ambs S., Bennett W.P., Merriam W.G., Ogunfusika M.O., Oser S.M., Harrington A.M., et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999, 91:86-88.
60. Zhao Z., Francis C.E., Welch G., Loscalzo J., Ravid K. Reduced glutathione prevents nitric oxide-induced apoptosis in vascular smooth muscle cells. Biochim Biophys Acta 1997, 1359:143-152.
61. Calmels S., Hainaut P., Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res 1997, 57:3365-3369.
62. Brockhaus F., Brune B. P53 accumulation in apoptotic macrophages is an energy demanding process that precedes cytochrome c release in response to nitric oxide. Oncogene 1999, 18:6403-6410.
63. Hongo F., Garban H., Huerta-Yepez S., et al. Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosation. Biochem Biophys Res Commun 2005, 336:692-701.